Increases common stock dividend by 17.6%
BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a first quarter 2011 dividend of $0.20 per share of common stock, representing a 17.6% increase over the company’s fourth quarter 2010 dividend of $0.17 per share. The dividend is equivalent to an annualized dividend of $0.80 per common share.
BioMed also announced that its board of directors has declared a dividend of $0.46094 per share of the company’s 7.375% Series A Cumulative Redeemable Preferred Stock for the period from January 16, 2011 through April 15, 2011.
Both dividends are payable on April 15, 2011 to stockholders of record at the close of business on March 31, 2011.
About BioMed Realty Trust
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company’s tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 85 properties, representing 147 buildings with approximately 12.2 million rentable square feet. The company’s properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants’ financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company’s target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to maintain the company’s investment grade credit ratings with the ratings agencies; failure to manage effectively the company’s growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company’s potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company’s dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Rick Howe, Director, Corporate Communications of BioMed Realty Trust, Inc., +1-858-207-5859
Web Site: http://www.biomedrealty.com
Tagged with: (NYSE: BMR) • BioMed Realty Trust • biotechnology • Business • Commercial Real Estate • Dividend • goverment agencies • Investment Property • Multifamily Property • New York Stock Exchange • Office Space • Pharmaceutical • Private Securities Litigation Reform Act • Real estate • Real Estate Investing • Real estate investment trust • REIT • Rental Property • scientific research • Stock • U.S. Securities and Exchange Commission
Filed under: Real Estate
Like this post? Subscribe to my RSS feed and get loads more!